Imaging NF-κB signaling in mice for screening anticancer drugs

Area of Science:

• Molecular Biology
• Oncology
• Biotechnology

Background:

• Nuclear factor kappa B (NF-κB) activation is linked to cancer development, making it a therapeutic target.
• Current in vitro assays for NF-κB activation lack in vivo imaging capabilities.
• Developing in vivo models is essential for effective drug screening and cancer therapy research.

Purpose of the Study:

• To provide detailed methods for utilizing the NF-κB-RE-luc animal model for in vivo imaging.
• To facilitate the study of anticancer drugs targeting NF-κB signaling pathways.
• To enable rapid assessment of transcriptional regulation in inflammatory diseases and cancer.

Main Methods:

• Utilizing male NF-κB-RE-luc (Oslo) mice and DBA/1, BALB/C-Tg (NF-κB-RE-luc (Oslo)) bioluminescent reporter models.
• Employing a transgene with NF-κB response elements and firefly luciferase for reporter gene expression.
• Inducing reporter activity via inflammatory stimuli like LPS and TNF-α.

Main Results:

• The NF-κB-RE-luc model allows for in vivo imaging of NF-κB activation.
• This model supports the study of transcriptional regulation of the NF-κB gene.
• Effective compound administration and imaging strategies are detailed.

Conclusions:

• The NF-κB-RE-luc animal model is a valuable tool for in vivo drug screening in cancer and inflammatory diseases.
• This model enhances the study of NF-κB signaling in a physiological context.
• The provided methods enable efficient utilization of the model for therapeutic research.